Coming Soon? A New Biologic

Coming Soon? A New Biologic

Coming Soon? A New Biologic For the past two decades, monoclonal antibodies (mAbs) have dominated the biologic drugs market. Doctors use these blockbuster products for a range of diseases, including many cancers and autoimmune diseases. In addition to their...
On A Tumor’s Turf

On A Tumor’s Turf

On A Tumor’s Turf  Solid tumors are generally considered more difficult to treat than blood cancers. For example, chimeric antigen receptor T-cell (CAR-T) therapy has been amazingly effective against blood cancers that failed to respond to other types of...
Killing Cancer At Its Stem Cell Origin

Killing Cancer At Its Stem Cell Origin

Killing Cancer When it comes to killing cancer, eradicating every single cell is the goal. But did you know there are different kinds of cancer cells? One specific type, called cancer stem cells (CSC), is catching the eye of drug developers. Discovered more than a...
Next-Generation CAR-T

Next-Generation CAR-T

The Race Is On Our last WEEKLY—Hacking the Immune Response—unveiled the science behind CAR-T and TCR, two immunotherapies under the microscope of the mainstream press. The well-deserved media attention highlights the ability of these “living drugs” to recognize and...
Hacking The Immune Response

Hacking The Immune Response

BIOPHARMA’S DARLING Immunotherapy is the current biopharma darling, garnering massive investment and media attention. Ranging from monoclonal antibodies to engineered T-cells, companies are rapidly learning how to harness the power of the immune system to fight...